With Covid-19 vac­cine in lim­bo, Chi­na's Fo­s­un inks $628M deal for a Pre­vnar 13 ri­val

Fo­s­un Phar­ma, BioN­Tech’s part­ner for its Covid-19 vac­cine in Chi­na, has its sights set on an­oth­er enor­mous vac­cine mar­ket.

The Shang­hai-based com­pa­ny has bought a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.